Get the Stockscreener App
1.42
5.33%
-0.08
After Hours:
1.42
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - Bluefield Daily Telegraph
Aytu BioPharma Earnings Alert: Key Financial Results Coming February 12What to Watch - StockTitan
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 - ACCESS Newswire
Aytu BioPharma to Present at LD Micro Main Event XVI Conference - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 - ACCESS Newswire
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - ACCESS Newswire
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso - ACCESS Newswire
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - ACCESS Newswire
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - ACCESS Newswire
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - ACCESS Newswire
Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St
Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World
An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com
Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World
Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance
Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan
Aytu BioPharma Disclosure Notification - AccessWire
Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance
Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan
Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com
Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Simply Wall St
Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com
Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks
Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com
Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch
Aytu BioPharma Achieves First-Ever Quarterly Profit of $1.5M, Reports 72% Margins | AYTU Stock News - StockTitan
Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500
Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia
Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail
Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St
AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire
2.34%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):